COVID-19 update: Covid-19-associated coagulopathy
COVID-19 update: Covid-19-associated coagulopathy
复制标题
DOI：
10.1007/s11239-020-02134-3
复制
发表时间：
2020-05-15
影响因子：
4
通讯作者：
Becker, Richard C.
中科院分区：
文献类型：
--
作者：
Becker, Richard C.
Covid-19 大流行引入了一系列器官特异性和系统性表型，其中一些是以前在病毒感染中观察到的，包括严重急性呼吸综合征 (SARS) 和其他似乎是 SARS-冠状病毒 (CoV)-2 所独有的表型。来自临床观察、尸检结果、体外和离体研究的推断以及动态模型的快速出现的信息正在为管理指南提供信息；然而，许多问题仍未得到解答，大多数领域尚未完成提供证据所需的临床试验。在需要仔细思考、反思和研究的许多问题中，有一个是全身性凝血病和获得性血栓形成倾向的发生机制，大多数病例的特征是静脉、动脉和微血管血栓形成的倾向。以下综述总结了对 Covid-19 相关凝血病的病理学、机制、诊断、管理、研究基础以及计划或正在进行的临床试验的新见解。
The Covid-19 pandemic has introduced an array of organspecific and systemic phenotypes-some previously observed in viral infections, including severe acute respiratory syndrome (SARS) and others that appear to be unique to SARS-coronavirus (CoV)-2. Rapidly emerging information from clinical observations, autopsy-based findings, extrapolations from in vitro and ex vivo studies and dynamic modeling are informing management guidelines; however, many questions remain unanswered and clinical trials that are required to provide evidence have not been completed in most areas. Among the many questions that require careful thought, reflection and investigation are the mechanism (s) underlying the development of a systemic coagulopathy and acquired thrombophilia characterized in a majority of cases by a proclivity for venous, arterial and microvascular thrombosis. The following review summarizes emerging insights into the pathobiology, mechanism (s), diagnosis, management, foundations for research and either planned or ongoing clinical trials for Covid-19-associated coagulopathy.